Piper Sandler assumed coverage on shares of Cara Therapeutics (NASDAQ:TVRD – Free Report) in a research report released on Thursday morning, MarketBeat reports. The firm issued an overweight rating and a $78.00 price target on the stock.
A number of other analysts also recently commented on TVRD. Wall Street Zen upgraded Cara Therapeutics to a “hold” rating in a research report on Saturday, May 24th. Oppenheimer began coverage on Cara Therapeutics in a research report on Wednesday, May 21st. They issued an “outperform” rating and a $65.00 price objective for the company.
Read Our Latest Stock Analysis on TVRD
Cara Therapeutics Stock Down 0.4%
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.
See Also
- Five stocks we like better than Cara Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Stocks Set to Double—And There’s Still Time to Buy
- What is the MACD Indicator and How to Use it in Your Trading
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
